Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost

Kuo, Chun Nan; Liao, Yi Hung; Kuo, Li Jen; Tsai, Hui Ju; Chang, Wei Chiao; Yen, Yun

doi:10.1016/j.jfma.2019.08.023

Cited by 64 publications

(56 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in 2011 the International Agency for Research on Cancer (5), which is a branch of the World Health Organization, classified non-ionizing radiofrequency radiation as possibly carcinogenic to humans categorizing it in group 2B (6). Breast cancer is one of the most commonly diagnosed cancers affecting women in Taiwan, and its incidence rate is gradually increasing worldwide (7). The known risk factors for breast cancer are obesity (8), smoking (9), genetic mutations such as breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene2 (BRCA2) which are tumor suppressor genes (9,10), family history (11,12), alcohol consumption (11)(12)(13)(14), exposure to estrogen hormones over an extended period (11,14), diethylstilbestrol and postmenopausal hormone therapy (15,16).…”

Section: Exposure To Radiofrequency Radiation Increases the Risk Of Bmentioning

confidence: 99%

Exposure to radiofrequency radiation increases the risk of breast cancer: A systematic review and meta‑analysis

et al. 2020

View full text Add to dashboard Cite

The present systematic review and meta-analysis investigated the association between exposure to radiofrequency radiation and the risk of breast cancer. The published studies that were available in PubMed, Embase, Cochrane Library, Ovid MEDLINE, CINAHL Plus, Web of Science, Airiti Library, Networked Digital Library of Theses and Dissertations and ProQuest until May 2020 were investigated. A total of eight studies (four case-control and four cohort studies) were eligible for quantitative analysis. A significant association between radiofrequency radiation exposure and breast cancer risk was detected [pooled relative risk (RR)=1.189; 95% confidence interval (CI), 1.056-1.339]. Subgroup analyses indicated that radiofrequency radiation exposure significantly increased the risk of breast cancer susceptibility among subjects aged ≥50 years (RR=2.179; 95% CI, 1.260-3.770). Pooled estimates revealed that the use of electrical appliances, which emit radiofrequency radiation, such as mobile phones and computers, significantly increased breast cancer development (RR=2.057; 95% CI, 1.272-3.327), while occupational radiofrequency exposure and transmitters did not increase breast cancer development (RR=1.274; 95% CI, 0.956-1.697; RR=1.133; 95% CI, 0.987-1.300, respectively). It was concluded that radiofrequency radiation exposure significantly increased the risk of breast cancer, especially in women aged ≥50 years and in individuals who used electric appliances, such as mobile phones and computers. In accordance with Preferred Reporting Items for Systematic Reviews and Meta-analysis, an evaluation protocol was prepared and registered with the PROSPERO database (registration no. CRD42018087283).

show abstract

Section: Exposure To Radiofrequency Radiation Increases the Risk Of Bmentioning

confidence: 99%

Exposure to radiofrequency radiation increases the risk of breast cancer: A systematic review and meta‑analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Due to detection and management limitations, late-stage NPC is considered to be a serious health problem in Taiwan and is the leading cause of cancer-related death [ 2 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ]. It is not known whether use of low-dose aspirin after the diagnosis of NPC is associated with OS and DSS rates in patients with NPC.…”

Section: Discussionmentioning

confidence: 99%

“…In Taiwan, the incidence rate is about 5–10 cases per 100,000 individuals each year, which is considered to be an intermediate risk for NPC [ 2 , 8 , 9 ]. Considering NPC prevalence is classified as intermediate, and treatment advancement trials for NPC are relatively low compared to other cancers that are common in Taiwan, such as colorectal, lung, and liver cancers [ 10 ], we sought to examine the association between aspirin use and the survival rates of patients with NPC in our healthcare system in order to improve the prognosis and outcome for patients with late-stage NPC [ 8 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Low-Dose Aspirin Use Significantly Improves the Survival of Late-Stage NPC: A Propensity Score-Matched Cohort Study in Taiwan

Luo

Chen

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: Aspirin use has been associated with improved survival rates in various cancers. However, it remains unclear if aspirin confers a survival benefit on patients with nasopharyngeal carcinoma (NPC). The aim of this study was to assess the associations between aspirin use and survival in different stages of NPC. Methods: This is a 10-year retrospective cohort study of NPC patients. A total of 565 NPC patients were recruited after we performed a 1:4 propensity score match between aspirin users and non–users. Cox regression models with adjusted covariates were employed to evaluate factors that influence the survival rate of NPC patients. Results: The Kaplan-Meier analysis revealed that the overall survival (p < 0.0001) and disease-specific survival (p < 0.0001) rates of 180-day aspirin users increased. Increased survival rates were also observed in 180-day aspirin users with Stages III and IV, T, N1 and 2, and N3 categories. Cox regression models indicated that factors, including aspirin use (univariate: HR = 0.28, 95% CI = 0.14–0.55, p < 0.001; multivariate: HR = 0.23, 95% CI = 0.12–0.46, p < 0.001), were independent prognostic factors for survival. Conclusions: Aspirin use for more than 180 days is associated with an increased survival rate and is a positive independent prognostic factor in NPC.

show abstract

“…Lung squamous cell carcinoma (LUSC) is the second most frequent subtype of NSCLC, accounting for about 40% of NSCLC (Chen et al, 2014), and its therapy and prognosis are still facing huge challenges. Nowadays, surgery and adjuvant chemotherapy are the standard treatment for stage I and II of NSCLC, however, molecular analysis is the key to select a first-line therapy for advanced cancer (Kuo et al, 2019). Large numbers of gene mutations have been reported to be served as specific biomarkers for diagnosis, treatment and prognosis for LUAD (lung adenocarcinoma) (Calvayrac et al, 2017), such as bevacizumab against VEGF.…”

Section: Introductionmentioning

confidence: 99%

Identification of key genes associated with progression and prognosis for lung squamous cell carcinoma

Ren

Peng

et al. 2020

PeerJ

View full text Add to dashboard Cite

Background Lung squamous cell carcinoma (LUSC) is a major subtype of lung cancer with limited therapeutic options and poor clinical prognosis. Methods Three datasets (GSE19188, GSE33532 and GSE33479) were obtained from the gene expression omnibus (GEO) database. Differentially expressed genes (DEGs) between LUSC and normal tissues were identified by GEO2R, and functional analysis was employed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool. Protein–protein interaction (PPI) and hub genes were identified via the Search Tool for the Retrieval of Interacting Genes (STRING) and Cytoscape software. Hub genes were further validated in The Cancer Genome Atlas (TCGA) database. Subsequently, survival analysis was performed using the Kapla–Meier curve and Cox progression analysis. Based on univariate and multivariate Cox progression analysis, a gene signature was established to predict overall survival. Receiver operating characteristic curve was used to evaluate the prognostic value of the model. Results A total of 116 up-regulated genes and 84 down-regulated genes were identified. These DEGs were mainly enriched in the two pathways: cell cycle and p53 signaling way. According to the degree of protein nodes in the PPI network, 10 hub genes were identified. The mRNA expression levels of the 10 hub genes in LUSC were also significantly up-regulated in the TCGA database. Furthermore, a novel seven-gene signature (FLRT3, PPP2R2C, MMP3, MMP12, CAPN8, FILIP1 and SPP1) from the DEGs was constructed and acted as a significant and independent prognostic signature for LUSC. Conclusions The 10 hub genes might be tightly correlated with LUSC progression. The seven-gene signature might be an independent biomarker with a significant predictive value in LUSC overall survival.

show abstract

Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost

Cited by 64 publications

References 72 publications

Exposure to radiofrequency radiation increases the risk of breast cancer: A systematic review and meta‑analysis

Exposure to radiofrequency radiation increases the risk of breast cancer: A systematic review and meta‑analysis

Low-Dose Aspirin Use Significantly Improves the Survival of Late-Stage NPC: A Propensity Score-Matched Cohort Study in Taiwan

Identification of key genes associated with progression and prognosis for lung squamous cell carcinoma

Contact Info

Product

Resources

About